BLTE Key Statistics, Chart & Performance
The current stock price of BLTE is 165.29 USD. In the past month the price increased by 20.26%. In the past year, price increased by 166.21%.
BLTE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.06 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 500.07B | ||
| MRK | MERCK & CO. INC. | 12.1 | 264.63B | ||
| PFE | PFIZER INC | 7.81 | 142.14B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.25 | 110.15B | ||
| ZTS | ZOETIS INC | 19.87 | 55.52B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.51 | 22.56B | ||
| VTRS | VIATRIS INC | 5.31 | 14.25B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.59 | 11.25B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.7 | 8.40B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.60B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.51B |
Related stock screener links
About BLTE
Company Profile
Belite Bio, Inc. engages in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
Company Info
BELITE BIO INC - ADR
12750 High Bluff Drive Suite 475
San Diego CALIFORNIA US
Employees: 25
Phone: 18582466240
BELITE BIO INC - ADR / BLTE FAQ
What does BELITE BIO INC - ADR do?
Belite Bio, Inc. engages in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 25 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
What is the stock price of BELITE BIO INC - ADR today?
The current stock price of BLTE is 165.29 USD. The price increased by 6.69% in the last trading session.
Does BELITE BIO INC - ADR pay dividends?
BLTE does not pay a dividend.
What is the ChartMill rating of BELITE BIO INC - ADR stock?
BLTE has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for BLTE stock?
12 analysts have analysed BLTE and the average price target is 188.02 USD. This implies a price increase of 13.75% is expected in the next year compared to the current price of 165.29.
BLTE Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BLTE. When comparing the yearly performance of all stocks, BLTE is one of the better performing stocks in the market, outperforming 98.81% of all stocks.
BLTE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BLTE. No worries on liquidiy or solvency for BLTE as it has an excellent financial health rating, but there are worries on the profitability.
BLTE Financial Highlights
Over the last trailing twelve months BLTE reported a non-GAAP Earnings per Share(EPS) of -1.92. The EPS decreased by -72.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.03% | ||
| ROE | -33.34% | ||
| Debt/Equity | 0 |
BLTE Forecast & Estimates
12 analysts have analysed BLTE and the average price target is 188.02 USD. This implies a price increase of 13.75% is expected in the next year compared to the current price of 165.29.